Welcome to our dedicated page for ImageneBio SEC filings (Ticker: IMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ImageneBio, Inc. filings document a Nasdaq-listed biotechnology issuer focused on IMG-007, its anti-OX40 receptor antagonist program for autoimmune and inflammatory diseases. Its 8-K reports disclose operating results, program updates, Regulation FD materials, private-placement and capital-structure matters, and officer or director changes.
Proxy materials cover annual meeting proposals, director elections, auditor ratification, equity incentive plan amendments, and executive compensation governance. The filing record also identifies the company’s common stock on The Nasdaq Capital Market and records formal disclosures tied to its completed reverse-merger corporate history.
ImageneBio, Inc. is a clinical-stage biopharmaceutical company developing therapies for immunological, autoimmune and inflammatory diseases. Its lead asset, IMG‑007 (olevaprubart), is a non-depleting anti‑OX40 monoclonal antibody initially targeted at atopic dermatitis and alopecia areata.
For the three months ended June 30, 2026, ImageneBio reported a net loss of $10,178 (in thousands), with research and development expenses of $6.7 million and general and administrative expenses of $5.1 million. Higher spending reflected expanding clinical work, public‑company costs, legal and IP activity, and stock‑based compensation.
For the six months ended June 30, 2026, net loss was $20,797 (in thousands). As of June 30, 2026, the company held $94,677 (in thousands) in cash and cash equivalents and $41,476 (in thousands) in marketable securities; management states this $136.2 million balance will fund operations for at least 12 months. In April 2026, a private placement of pre‑funded warrants raised $30.0 million to support development of olevaprubart while the company progresses a Phase 2b atopic dermatitis trial and prepares a Phase 2 alopecia areata study.
ImageneBio, Inc. reported second-quarter 2026 results and updated progress on its lead program, olevaprubart, an OX40-targeting, non-T cell-depleting monoclonal antibody for autoimmune and inflammatory diseases. The Phase 2b ADAPTIVE trial in moderate-to-severe atopic dermatitis is advancing, with patients entering a long-term extension, and a Phase 2 alopecia areata trial is planned.
Following a $30 million PIPE financing in April 2026, the company ended June 30, 2026 with $136.2 million in cash, cash equivalents and marketable securities and expects these resources to fund planned operations into the first quarter of 2028.
For the quarter, research and development expenses were $6.7 million and general and administrative expenses were $5.1 million, for total operating expenses of $11.8 million. Net loss was $10.2 million, or $0.63 per share, compared with $10.7 million, or $4.46 per share, in the 2025 quarter. Total stockholders’ equity was $142,074 (in thousands) as of June 30, 2026.
ImageneBio, Inc. filed an initial Form 3 identifying Yanina Grant-Huerta as its Chief Financial Officer and reporting person. The data shows no insider transactions, holdings entries, or derivative positions, and references an Exhibit 24 Power of Attorney authorizing filings on her behalf.
ImageneBio, Inc. Chief Executive Officer Kristin Yarema reported RSU-related changes in ownership. On July 25, 2026, 38,376 restricted stock units were exercised into 38,376 shares of common stock at $0.0000 per share. An additional 115,129 unvested RSUs from a July 28, 2025 grant were reclassified and now appear as common stock holdings; no purchase or sale transactions are reported.
ImageneBio, Inc. filed a prospectus supplement covering the proposed resale, from time to time, of 2,508,337 shares of common stock by selling stockholders under an existing Form S-1. The common stock trades on the Nasdaq Capital Market under the symbol IMA; the last reported sale price was $5.97 per share on July 22, 2026.
The company also appointed Yanina Grant-Huerta as Chief Financial Officer, principal financial officer and principal accounting officer effective July 20, 2026. Her employment terms include a $450,000 annual base salary, eligibility for an annual discretionary bonus targeted at 40% of base salary, an initial option to purchase 95,000 shares, and 65,000 restricted stock units, each vesting over four years. She will participate as a C-suite officer in the company’s Severance and Change in Control Plan, which can provide up to 12 months of salary, a 100% target bonus payout, continued health benefits for up to 12 months, and full equity acceleration upon a qualifying covered termination during a change in control period.
Effective July 24, 2026, Chief Medical Officer Benjamin Porter-Brown will transition from a full-time role to a consulting position, continuing to advise on clinical development and strategy.
ImageneBio, Inc. appointed Yanina Grant-Huerta as Chief Financial Officer, principal financial officer and principal accounting officer effective July 20, 2026, succeeding CEO Kristin Yarema, Ph.D., in her interim finance role. Grant-Huerta previously held senior finance positions at Atara Biotherapeutics and Amgen.
Under an employment agreement, she receives an annual base salary of $450,000, is eligible for a discretionary annual bonus equal to 40% of base salary, and is granted 65,000 restricted stock units and a stock option for 95,000 shares, each vesting over four years, subject to continued employment. She will participate in ImageneBio’s Severance and Change in Control Plan, which provides 12 months of salary and up to 12 months of health benefits, plus an additional lump sum equal to 100% of target bonus and full equity acceleration upon certain covered terminations during a change in control period. Effective July 24, 2026, Chief Medical Officer Benjamin Porter-Brown will transition from a full-time executive role to a consulting clinical development and strategic advisory position.
ImageneBio, Inc. Principal Accounting Officer Robert B. Lally reported selling a total of 3,196 shares of Common Stock in open-market transactions on July 16–17, 2026. Sales included 1,671 shares at a weighted average price of $5.50 (range $5.45–$5.635) and 1,525 shares at $5.34 (range $5.32–$5.3527).
ImageneBio, Inc. filed a prospectus supplement to its Form S-1 registering the resale or other disposition of 2,508,337 shares of Common Stock. The supplement incorporates portions of a Form 8-K noting that Senior VP of Finance and Operations Robert Lally gave notice of resignation, effective July 22, 2026. The supplement states the last reported sales price was $6.02 per share on June 26, 2026 and that the selling stockholders, identified in the prospectus, propose to offer those shares from time to time.
Imagenebio, Inc. reported that Robert Lally, its Senior Vice President of Finance and Operations and principal accounting officer, has resigned. He notified the company on June 22, 2026, and his resignation will be effective July 22, 2026. The company stated that his departure is not due to any disagreement with Imagenebio. Management plans to conduct a search for his replacement.
ImageneBio, Inc. director Jonathan Jian Wang received a grant of stock options covering 15,600 shares of common stock. The options have an exercise price of $5.45 per share and expire on June 16, 2036.
The options vest in full on the earlier of the first anniversary of the grant date, the company’s next annual meeting, or a change of control under the 2025 Equity Incentive Plan.